Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
Transaction summary Metric Value Shares sold (direct) Transaction value Post-transaction common shares (direct) Post-transaction value (direct ownership) $10.60 million Transaction value based on SEC Form 4 weighted average purchase price ($17.64); post-transaction value based on April 14, 2026 market close ($17.50). Key questions How does this sale compare to Markus Warmuth's previous selling activity? This 8,000-share sale is the largest of his three open-market dispositions since January 2026, exceeding the two prior trades of 5,466 shares each, and aligns with a recent pattern of quarterly liquidity events. However, another sale of 10,135 shares, also in January, was larger. What was the prevailing market context at the time of the transaction? The shares were sold at a weighted average price of around $17.64 per share, with the 1-year share price return exceeding 300% as of the transaction date. What is the impact of this transaction on Warmuth's over
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid TumorsGlobeNewswire
- Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics (GLUE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLUE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Monte Rosa Therapeutics (GLUE) had its price target lowered by Guggenheim from $34.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
GLUE
Sec Filings
- 4/22/26 - Form SCHEDULE
- 4/16/26 - Form 144
- 4/15/26 - Form 4
- GLUE's page on the SEC website